Skip to content

TALISMAN-2.5 Pilot

Exploratory study investigating oxygen saturation responses during intermittent hypoxia across 4-week repeated exposure to intermittent hypoxia in individuals with Parkinson’s disease. - TALISMAN 2.5 Pilot

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58476
Enrollment
10
Registered
2025-09-10
Start date
2026-04-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease Parkinson's disease

Interventions

45 minutes of normobaric intermittent hypoxia (FiO2 0.163 for 5 minutes interspersed with 5 minutes normoxia) will be delivered via a hypoxicator (a device that titrates decreased fractional oxygen fr

Sponsors

Radboud Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Informed consentClinical diagnosis of PD by a movement disorder specialized neurologist.Hoehn and Yahr staging 1-3 (indicating mild to moderate PD)Availability of an observant (partner, family member, friend, other relative) during at-home interventions

Exclusion criteria

Exclusion criteria: Individuals with diseases leading to restrictive and obstructive pulmonary diseases, sleep apnea and cardiac output deficits, such as pulmonary fibrosis, COPD, sleep apnea or excessive alcoholic intake, and congestive heart failure respectivelyIndividuals with coronary artery disease NYHA classes III and IV Individuals with shortness of breath or other airway or breathing-related inconvenience related to lack of dopaminergic medicationIndividuals with active deep brain stimulationHematological disordersStop criteria during session 1

Design outcomes

Primary

MeasureTime frame
blood saturation levels (SpO2)

Secondary

MeasureTime frame
MDS-UPDRS scores, Subjective status medication usehypoxic ventilator response (to first and last session)Plasma biomarker hemoglobin 

Countries

Netherlands

Contacts

Public ContactN Stortelder

Radboud Universitair Medisch Centrum

mayke.lamers@radboudumc.nl(024) 361 42 73

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 3, 2026